Digital repository of Slovenian research organisations

Show document
A+ | A- | Help | SLO | ENG

Title:Ticagrelor is associated with increased rosuvastatin blood concentrations in patients who have had a myocardial infarction
Authors:ID Dermota, Tjaša (Author)
ID Jug, Borut (Author)
ID Trontelj, Jurij (Author)
ID Božič Mijovski, Mojca (Author)
Files:.pdf PDF - Presentation file, download (550,79 KB)
MD5: 61942DE61D70B7CF17CF93196E7D5648
 
URL URL - Source URL, visit https://link.springer.com/article/10.1007/s40262-025-01489-1
 
Language:English
Typology:1.01 - Original Scientific Article
Organization:Logo UKC LJ - Ljubljana University Medical Centre
Abstract:Aims: The primary objective of this study was to determine whether concomitant therapy with ticagrelor and rosuvastatin affects rosuvastatin plasma concentrations in patients receiving rosuvastatin 40 mg/day after myocardial infarction. Methods: We included 93 patients who had experienced a myocardial infarction and were receiving high-dose rosuvastatin 40 mg/day and a P2Y12 receptor antagonist, either ticagrelor, prasugrel or clopidogrel. We used liquid chromatography with tandem mass spectrometry to measure rosuvastatin plasma concentrations after liquid–liquid extraction. Results: Rosuvastatin plasma concentrations (9.7 ng/mL) were approximately twice as high in patients receiving ticagrelor therapy as in those receiving prasugrel (5.1 ng/mL, p<0.001) or clopidogrel (5.0 ng/mL, p=0.009), and ticagrelor was an independent factor influencing rosuvastatin concentrations. In addition, creatinine levels were associated with increased rosuvastatin concentrations (p=0.039). Conclusion: Our results suggest an important pharmacokinetic interaction between ticagrelor and rosuvastatin, leading to approximately two-fold higher rosuvastatin plasma concentrations in those receiving concomitant ticagrelor than in those receiving prasugrel or clopidogrel. The association is significant and independent of other potential factors influencing rosuvastatin levels, indicating its potential clinical relevance.
Keywords:clopidogrel, drug interactions, rosuvastatin, pharmacokinetics, ticagrelor, concomitant therapy, pharmacokinetic interaction, myocardial infarction
Publication status:Published
Publication version:Version of Record
Year of publishing:2025
Number of pages:Str. 565–571
Numbering:Vol. 64, no. 4
PID:20.500.12556/DiRROS-24278 New window
UDC:616.1
ISSN on article:1179-1926
DOI:10.1007/s40262-025-01489-1 New window
COBISS.SI-ID:245769987 New window
Note:Nasl z nasl. zaslona; Opis vira z dne 18. 8. 2025;
Publication date in DiRROS:24.11.2025
Views:84
Downloads:50
Metadata:XML DC-XML DC-RDF
:
Copy citation
  
Share:Bookmark and Share


Hover the mouse pointer over a document title to show the abstract or click on the title to get all document metadata.

Record is a part of a journal

Title:Clinical pharmacokinetics
Shortened title:Clin. pharmacokinet.
Publisher:Adis International, Adis International
ISSN:1179-1926
COBISS.SI-ID:519138585 New window

Document is financed by a project

Funder:ARIS - Slovenian Research and Innovation Agency
Project number:P3-0308-2019
Name:Ateroskleroza in tromboza

Licences

License:CC BY-NC 4.0, Creative Commons Attribution-NonCommercial 4.0 International
Link:http://creativecommons.org/licenses/by-nc/4.0/
Description:A creative commons license that bans commercial use, but the users don’t have to license their derivative works on the same terms.

Back